Vaccines and global collaboration in the age of COVID-19
Since its emergence in Wuhan in late 2019, no country has been immune to the public health and economic impact of COVID-19. With the death toll of COVID-19 having surpassed 1 million people and the World Bank forecasting a 5.2 per cent contraction in global GDP, this pandemic has emerged as a devastating global threat.
In the battle to safeguard populations and restart economies, the hunt to develop a safe and effective vaccine is central to international efforts. United behind this common goal, businesses, research institutes and governments have come together to collaborate and cooperate in new and innovative ways, spurring the development of a COVID-19 vaccine at record speeds. With nine vaccine candidates already in Phase 3 and conducting large scale efficacy trials, this rapid development demonstrates the innovative capacity of the global healthcare sector.
Beyond vaccine development, this crisis has forced into view the need to consider future pandemic preparedness and the crucial role that vaccination can play throughout a person’s life beyond infancy, particularly among the most vulnerable in society, such as older adults and people with chronic conditions. COVID-19 has highlighted the devastating impact of infectious disease on society – against this backdrop, it is even more important for stakeholders across the health ecosystem to take steps to future-proof against unforeseen global health crises.
This webinar, organised by Asia House in partnership with Pfizer, will bring together key stakeholders to discuss collaboration across the healthcare system that has emerged and strengthened in the age of COVID-19.
This online event takes place on 19 November, 09:00 – 10:15 UK time. To register interest in this event, please email Edward Danks, Content Producer: email@example.com
- Janine Small, Regional President of International Developed Markets – Vaccines Division, Pfizer
- Tim Colley, International Director, Vaccine Task Force, Department for Business, Energy and Industrial Strategy (BEIS)
- Heidi Larson, Director, Vaccine Confidence Project, London School of Hygiene & Tropical Medicine
- Michael Lawrence, Chief Executive, Asia House (moderator)